Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.38 |
| ▸ | ITGAV | P06756 | 5/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23083070 | 0.92 | ITGB3 (0.41) | ITGB3ITGAVITGA2BHDAC8CA12 | |
| SCHEMBL23083114 | 0.85 | ITGB3 (0.41) | ITGB3ITGAVITGA2BCRBNABCG2 | |
| SCHEMBL23083186 | 0.83 | ITGB3 (0.40) | ITGB3ITGAVITGA2BCRBNABCG2 | |
| SCHEMBL23082988 | 0.81 | ITGB3 (0.50) | ITGB3ITGAVITGA2BCRBNABCG2 | |
| SCHEMBL23083062 | 0.79 | ITGB3 (0.45) | ITGB3ITGAVITGA2BCRBN | |
| SCHEMBL23083052 | 0.78 | ITGB3 (0.42) | ITGB3ITGAVITGA2B | |
| SCHEMBL23082986 | 0.78 | ITGB3 (0.44) | ITGB3ITGAVITGA2BCRBN | |
| SCHEMBL23083164 | 0.78 | ITGB3 (0.47) | ITGB3ITGAVITGA2BCRBNABCG2 | |
| SCHEMBL23083060 | 0.78 | ESR1 (0.34) | ITGB3ITGAVITGA2BCRBNABCG2 | |
| SCHEMBL23082997 | 0.77 | OPRM1 (0.34) | ITGB3ITGAVITGA2BCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | ITGB3 4/4885ITGAV 1/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.